Cert Endocrinology(SA) Phys Practice Questions - CMSA Sub-specialty Certificate In Endocrinology And Metabolism Exam

Access More Questions

According to the 2024 SEMDSA guidelines for type 2 diabetes mellitus, which pharmacological class is recommended as first-line add-on therapy to metformin in a patient with established atherosclerotic cardiovascular disease (ASCVD), regardless of baseline HbA1c?

GLP-1 receptor agonist with proven CV benefit or SGLT2 inhibitor Dipeptidyl peptidase-4 (DPP-4) inhibitor Thiazolidinedione (e.g., pioglitazone) Second-generation sulfonylurea (e.g., gliclazide MR)

Correct Answer:

GLP-1 receptor agonist with proven CV benefit or SGLT2 inhibitor

Access more questions from this quiz

Continue to Cert Endocrinology(SA) Phys Practice Questions - CMSA Sub-specialty Certificate in Endocrinology and Metabolism Exam for more practice questions and the full quiz experience.

Access More Questions